FAKTOR-ZERTIFIKAT - BOSTON SCIENTIFIC | Real-time Bid/Ask 08:00:51 2024-06-17 EDT | ||
| 2.17 EUR / 2.24 EUR | +1.61% |
|
| Current month | -16.86% | ||
| 1 month | -30.45% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BOSTON SCIENTIFIC CORPORATION
| Date | Price | Change |
|---|---|---|
| 24-06-17 | 2.07 | -4.61% |
| 24-06-14 | 2.17 | +0.46% |
| 24-06-13 | 2.16 | +5.37% |
| 24-06-12 | 2.05 | -3.30% |
| 24-06-11 | 2.12 | +2.91% |
Delayed Quote Börse Stuttgart
Last update June 17, 2024 at 04:49 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | BOSTON SCIENTIFIC CORPORATION |
| Issuer | J.P. Morgan |
| WKN | JK23SQ |
| ISIN | DE000JK23SQ5 |
| Date issued | 2024-02-23 |
| Strike | 87.73 $ |
| Maturity | Unlimited |
| Parity | 4.93 : 1 |
| Emission price | 10.1 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.23 € |
|---|---|
| Lowest since issue | 1.96 € |
| Spread | 0.07 € |
| Spread % | 3.27% |
Company Profile
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows:
- cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%);
- endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ;
- neuromodulation (2%).
The United States account for 59.2% of net sales.
Sector
-
Ratings for Boston Scientific Corporation
Trading Rating
Investor Rating
ESG Refinitiv
A-
Consensus: Boston Scientific Corporation
Sell
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
76.76
USD
Average target price
82.26
USD
Spread / Average Target
+7.16%
- Stock Market
- Certificates
- Certificat
